RE SOURCES - Laboratoires Expanscience€¦ · the daily diaper care that changes everything...

SOURCESRE2 0 1 5 A N N U A L R E P O R T

S A G A p.30

Corporate Social Responsibility:Expanscience introduces its “Better Living Program”

S O C IE T Y p.14OSTEOARTHRITIS: A CHALLENGE FOR MOBILITY

R E P O R T IN G p.26BEHIND THE SCENES IN ÉPERNON

U ND E R S TA ND IN G p.11EXPERTISE IN SKIN HEALTH

CLINICALLY-PROVEN EFFICACY

with complete safety for your baby

PRESERVETHE BEAUTY

OF YOUR SKIN

STRETCH MARKS

SKIN COMFORT

FIRMING

BREASTFEEDING

MUSTELA, THE SKINCARE EXPERT FOR BABIES AND MOTHERS-TO-BE FOR OVER 60 YEARS.®

* A

ll M

ust

ela

® M

ate

rnit

y f

orm

ula

s h

ave

be

en

eval

uat

ed

to

be

su

itab

le f

or

bre

astf

ee

din

g.

*100%COMPATIBLEWITH BREASTFEEDING

SAFE FORMOTHER AND BABY

CLINICALLY-PROVEN EFFICACY

with complete safety for your baby

PRESERVETHE BEAUTY

OF YOUR SKIN

STRETCH MARKS

SKIN COMFORT

FIRMING

BREASTFEEDING

MUSTELA, THE SKINCARE EXPERT FOR BABIES AND MOTHERS-TO-BE FOR OVER 60 YEARS.®

* A

ll M

ust

ela

® M

ate

rnit

y f

orm

ula

s h

ave

be

en

eval

uat

ed

to

be

su

itab

le f

or

bre

astf

ee

din

g.

*100%COMPATIBLEWITH BREASTFEEDING

SAFE FORMOTHER AND BABY

Cover © Getty Images

Over the life of a company, some years have an especially decisive impact. At Laboratoires Expanscience, 2015 was undoubtedly one of those years. It’s been decisive for the success of our products worldwide, for the production records set by our manufacturing site, and above all for the milestones we have reached, the transformations we have successfully navigated and the ambitions we have set for ourselves.In 2015, for the first time, our international sales exceeded our sales in France. Moreover, in 2015 we adopted a new business model in France for Piasclédine 300, our drug for the treatment of osteoarthritis. And in 2015 we drafted a five-year plan of commitments with regard to Corporate Social Responsibility, with the aim of pledging new commitments between now and 2020.

All of these events are described in this fourth issue of Re Sources and make 2015 a pivotal year and a collective human accomplishment. These events are the result of strategic decisions but also, first and foremost, the outgrowth of our employees’ commitment to innovate in order to protect the health of our patients and consumers. You can read what those employees have to say throughout this report, and you’ll quickly understand why we have chosen to feature their comments prominently!

Enjoy your reading!

The editorial team

Since 2009, Laboratoires Expanscience has been a signatory of the Charter for Responsible Communications from the French Advertisers Association.

Laboratoires Expanscience’s contribution to sustainable development has been recognized as exemplary by the AFAQ 26000 assessment.

The environmental management system that Laboratoires Expanscience has developed for its R&D and production activities is ISO 14001-certified.

Laboratoires Expanscience is a member of the UEBT for protecting biodiversity and complying with fair trade regulations.

Laboratoires Expanscience has been a signatory of the United Nations Global Compact since 2004.

DIRECTOR OF PUBLICATIONS Jean-Paul Berthomé

EDITORIAL DIRECTORSébastien Sillon

EDITOR-IN-CHIEFEmmanuelle Dumas

EDITORIAL MANAGERNolwenn Sassier-Le Goff

DESIGN, CREATION, PRODUCTION AND PRINTINGAristophane

This annual report is published by Laboratoires Expanscience. PHOTO©Getty ImagesFotoliaExpanscience photo libraryThomas Deron

By printing this annual report on FSC and European Ecolabel approved offset paper, Expanscience is helping to protect the environment.This document has been printed by Ateliers Réunis, an Imprimvert-certified printer.

2015: A PIVOTAL

YEAR

EDITORIAL

THE DAILY DIAPER CARE

THAT CHANGES EVERYTHING

RELIEVES2

REPAIRS31

PREVENTS

DESIGNED TO MINIMIZE ENVIRONMENTAL IMPACTOF NATURAL ORIGIN

INGREDIENTS98 PHENOXYETHANOLPARABEN - PHTHALATE

OUR COMMITMENTS

IRRITATION AND REDNESS

HIGH T OL ER A NCEF R A G R A N C E0% P R E S E R VAT I V E

MUSTELA®, IT ALL STARTS WITH SKIN

MUSTELA_A4_Change_UK.indd 1 06/04/2016 15:24

THE DAILY DIAPER CARE

THAT CHANGES EVERYTHING

RELIEVES2

REPAIRS31

PREVENTS

DESIGNED TO MINIMIZE ENVIRONMENTAL IMPACTOF NATURAL ORIGIN

INGREDIENTS98 PHENOXYETHANOLPARABEN - PHTHALATE

OUR COMMITMENTS

IRRITATION AND REDNESS

HIGH T OL ER A NCEF R A G R A N C E0% P R E S E R VAT I V E

MUSTELA®, IT ALL STARTS WITH SKIN

MUSTELA_A4_Change_UK.indd 1 06/04/2016 15:24

0 3

06BENCHMARKS

Key figures for 2015

08HIGHLIGHTS

One year, 10 new developments

14SOCIETY

Osteoarthritis: a challenge for mobility

21FEATUREAt the heart

of Laboratoires Expanscience

30SAGA

Corporate social responsibility: Expanscience

introduces its “Better Living Program”

34HERE & THERE

A stronger presence on 5 continents

39SPONSORSHIP

A commitment without borders

11UNDERSTANDING

Expertise in skin health

INTERVIEWJean-Paul Berthomé CEO

04REPORTINGIR&D and production: behind the scenes in Épernon

26

SELECTED ITEMSFocus on Expanscience products

17

2 0 1 5 A N N U A L R E P O R T E X P A N S C I E N C E

INTERVIEW

JEAN-PAUL BERTHOMÉ

/Laboratoires Expanscience

CEO

HOW DO YOU REFLECT ON 2015?

— The past year has been one in which Expanscience demonstrated its ability to adapt and pursue further international growth. In order to meet the challenge of Piasclédine 300, our drug for the treatment of osteoarthritis, being removed from the list of reimbursable products in France, we adopted a new business model, called OTX*, and have succeeded in cementing our leadership in pharmacies. Thanks to our energetic distributors and the opening of new subsidiaries - five in three years, notably in Canada and Russia in 2015 - we passed a critical milestone: for the first time in our history, more than half of our turnover came from outside France.

WHAT ASSESSMENT WOULD YOU GIVE FOR EACH BUSINESS?

— In a challenging environment, we have managed to expand our rheumatology business, thanks to our overall turnover from the portfolio and double-digit growth abroad. With regard to our dermo-cosmetics business, the revitalization of our Mustela Bébé and Mustela Maternity product lines has borne fruit, and Mustela’s market share has increased in every country, with a strong contribution from our subsidiaries in Turkey, Belgium, Brazil and France. Cosmetic active ingredients also posted solid growth, thanks to the launch of two active ingredients and our efforts to capture new customers. Lastly, the introduction of our Finhair Gé drug for androgenic alopecia, and continued strong sales of Effizinc, used to treat mild acne, have boosted growth in dermatology.

IN 2010 EXPANSCIENCE ADOPTED A NUMBER OF COMMITMENTS FOR 2015 WITH REGARD TO CORPORATE SOCIAL RESPONSIBILITY (CSR). WHAT HAVE BEEN THE RESULTS?

— I’m proud of the path we have taken. Thanks to the energetic efforts of the entire workforce, we have fulfilled our commitments. Our CSR policy is an increasingly integral part of the company, and truly sets us apart in the eyes of our target markets. It has won external recognition in the form of 12 different awards the company has received since 2012. Insofar as Expanscience and its ecosystem are confronted with new challenges (international expansion,

environmental and social concerns, changing community attitudes toward businesses, etc.), we have defined a new road map for the next five years. We’re calling this road map our “Better Living Program,” and it contains our commitments for 2020, all aimed at taking better care of each of our communities, including patients, consumers and employees.

DURING THIS PAST YEAR YOU LED AN INITIATIVE REGARDING YOUR COMPANY’S IDENTITY AND CULTURE. WHAT WAS YOUR OBJECTIVE?

— During Expanscience’s current growth phase, we saw a need to look once again at the powerful and unifying characteristics that bind our workforce together, and the ways our employees strive for innovation each day to preserve the health of our patients and consumers.Our aim was not merely to promote unity and a sense of belonging among our employees, but also to make us more attractive to the candidates we hire in the future, notably overseas. Those considerations prompted us to adopt a campaign to voice our conviction that, as an employer: “Each one’s potential makes everyone’s success.”

WHAT ARE YOUR AMBITIONS FOR 2016?

— We have objectives for advancing and capturing growth in each of our markets. First, we’re aiming for double-digit growth for our Mustela brand in the international market. This will be driven by expanded market share in Asia, a launch in the South African market, our continued positioning as a Premium brand in response to strong demand worldwide, and our ongoing campaign to roll out our new Mustela Maternity product line. In rheumatology, too, the international market will be instrumental in driving growth, with the introduction of Piasclédine 300 in Brazil. We also intend to continue our progress in France in the market for arthritis and osteoporosis by strengthening our OTX model regarding Piasclédine 300 – which test laboratory was successful - and by introducing a first-line treatment for osteoporosis in menopausal women. Growth in our cosmetic active ingredients business will be led by a portfolio enhanced with new, natural-origin active ingredients that offer sensory appeal. Lastly, innovation remains our priority: we’ll be maintaining our EV.E.I.L.S** research program in the fields of infant and pregnant women skin, which in 2016 will continue to power our expertise in skin health and our future innovations.

WHAT DO YOU THINK EXPANSCIENCE WILL LOOK LIKE IN 2020?

— It will look like a company that acquired the resources to change and adapt, and that goes beyond its products to become something even more valuable for patients and consumers. It will also be a more international company, with 75% of its turnover generated outside of France.

* A model based on over-the-counter sales of Piasclédine 300 in connection with a medical prescription

** Evaluation of Early Infant Life: the Skin

“ THE EXPANSCIENCE OF THE FUTURE IS A COMPANY WILLING TO ADAPT, WITH ETHICS, RESPECT AND A RESPONSIVE ATTITUDE. ALONG WITH ITS PRODUCTS, IT OFFERS AN ARRAY OF SERVICES TO PATIENTS AND CUSTOMERS THROUGHOUT THE WORLD. ”

0 52 0 1 5 A N N U A L R E P O R T E X P A N S C I E N C E

BENCHMARKS

TURNOVER BY ACTIVITY:

KEY FIGURES

FOR 2015

36.5%

RHEUMATOLOGY

1.4%

COSMETIC ACTIVE INGREDIENTS

0.1%

INDUSTRY

58.9%

DERMO-COSMETICS

3.1%

DERMATOLOGY

€272.3 MIN TURNOVER

0 6 B E N C H M A R K S

977EMPLOYEES

14SUBSIDIARIES: AUSTRALIA, BELGIUM, BRAZIL,

CANADA, FRANCE, ITALY, MEXICO, POLAND,

PORTUGAL, RUSSIA, SPAIN, SWITZERLAND,

TURKEY, UNITED STATES

85DISTRIBUTING COUNTRIES

66MILLION PRODUCTS

MANUFACTURED

843PATENTS REGISTERED

WORLDWIDE

48.7 %FRANCE

51.3 %INTERNATIONAL

TURNOVER

BY GEOGRAPHICAL AREA


HIGHLIGHTS

The new Mustela Maternity line is designed to preserve the skin’s beauty while ensuring the baby’s safety, with seven expert treatments specially formulated to address the various ways skin can change during pregnancy. Guaranteed safe for mother and child, clinically proven to be effective, enjoyable to use and made with ingredients of natural origin whenever possible, this new line of Mustela products bears all the hallmarks of the Mustela name.

The expanscience.com website has been completely redesigned to more closely reflect the company’s identity. Contemporary, user-friendly and intuitive, the new site immediately envelops visitors in the world of Expanscience, from its know-how and services in the fields of osteoarthritis and skin health to its expertise in innovation, research and development, along with an introduction to the company’s products and its CSR policy. As a true showcase for Expanscience, it can be viewed on any medium (computer, tablet, smartphone).

As part of the Research on Osteo Arthritis Diseases (ROAD) project and in partnership with the Arthritis Foundation, Laboratoires Expanscience are joining forces with seven basic research units at France’s Institute of Health and Medical Research (INSERM) and National Center for Scientific Research (CNRS). The goal of the three-year program is to identify new biomarkers for use in developing innovative therapeutic strategies in the treatment of osteoarthritis.

O4WORKING ALONGSIDE RESEARCHERS

O1FOR FEELING GOOD DURING PREGNANCY

At a time when slow-acting anti-rheumatic drugs are no longer reimbursable in France, Piasclédine 300 has managed to cement its leadership status in pharmacies and among healthcare professionals through an emphasis on medical prescriptions. Internationally, the drug has logged double-digit growth in turnover.

O3OSTEOARTHRITIS: STRONGER MARKET DOMINANCE

O2A NEW DIGITAL SHOWCASE

ONE YEAR,

10 NEW

DEVELOPMENTS

0 8 H I G H L I G H T S

Expanscience was awarded the top prize for its Corporate Social Responsibility policy in the “Governance, Ethics and Responsible Management” category of the first-ever 2015 CSR Awards, hosted by Les Entreprises du Médicament (LEEM), a trade organization for the French pharmaceutical industry. The independent jury specifically praised the comprehensive nature of the company’s policy, in which every employee has a role to play; its deployment of an action plan through a network of internal liaisons; and the way the policy was developed in cooperation with company stakeholders.

For the first time in the history of Laboratoires Expanscience, and thanks to the strong performance of the Mustela brands and Piasclédine 300 on every continent, turnover from international sales surpassed that of sales in France, which also rose. This brings the company one step closer to an objective that Expanscience has set for 2020: to obtain 75% of its turnover from international markets.

O6INTERNATIONAL SALES: A DECISIVE MILESTONE

O5CSR: EXPANSCIENCEHONORED ONCE AGAIN

Capitalizing on its expertise in plant extraction and the know-how of its research teams, Expanscience expanded its offerings for the cosmetics industry with two innovative and eco-designed active ingredients. Pixalia, responsibly sourced from Burkina Faso, acts on oily, acne-prone skin in women and teenagers. Made from maca, a plant cultivated in Peru, Macaline marks Expanscience’s entry into the segment of active ingredients for the body, thanks to its threefold slimming, firming and draining action.

10TWO NEW COSMETIC ACTIVE INGREDIENTS

Mustela has created “Mustela & me” an innovative support program to ensure mothers have a fulfilling pregnancy. This free app, available in five languages, offers daily tips and advice before, during and after pregnancy. It was elected “Best Sport, Health and Wellness” app at France’s 2015 App Awards six months after its launch.

O7THE APP FOR NEW MOTHERS AND MOTHERS-TO-BE

At the 23rd World Congress of Dermatology, held in Vancouver, Expanscience presented the results of 10 years of research into the skin of newborns and children to more than 100 opinion-leaders in the field of dermatology from around the world. The WCD is a major event on the calendar of the international dermatology community.

09EXPANSCIENCE AT THE VANCOUVER CONGRESS

To accelerate Mustela’s international growth, Expanscience opened two new subsidiaries in Canada and Russia - high-potential markets where the dermo-cosmetics brand was previously distributed by partners. Five new subsidiaries have been created in the span of three years.

O8MUSTELA MOVES INTO CANADA AND RUSSIA


WE HAVE OPTED FOR “NATURALNESS” AS A WAY TO PRESERVE DELICATE SKIN MORE EFFECTIVELY. WE SELECT THE BEST INGREDIENTS OF NATURAL ORIGIN IN ORDER TO PROVIDE SAFE, EFFECTIVE PRODUCTS THAT ARE A PLEASURE TO USE AND FRIENDLY TO BOTH PEOPLE AND THE ENVIRONMENT.

QUANTIFIED NATURAL ORIGIN

Developed in collaboration with healthcare professionals, including pediatricians and dermatologists, the products in the Mustela Bébé and Mustela Maternity lines contain an average of 92% and 86% ingredients of natural origin respectively.

PRODUCTS THAT CONTAIN…

Mustela products have three types of ingredients:— “natural” ingredients (water, oils, plant-based butters) that come directly from nature;— ingredients of natural origin (emulsifiers, gelling agents) that are obtained from nature but processed using certain chemical procedures;— selected synthetic ingredients (such as pH regulators), added solely when no appropriate natural alternative is available.

PRODUCTS THAT DO NOT CONTAIN...

To meet the needs of natural, sensitive baby skin, Mustela products are free of the following substances:Ammonium Lauryl Sulfate, Sodium Lauryl Sulfate, p-Phenylenediamine and similar compounds, Phenoxyethanol, Paraben, Phthalates, BHA, Benzophenone, Ethylhexyl Methoxycinnamate, Cyclotetrasiloxane, Triclosan.

A NATURAL OILFOR PREVENTING STRETCH MARKS

Mustela has always looked to the plant world to source the main active ingredients that make up its products. Made from 99% ingredients of natural origin*, Mustela Maternity Stretch Marks Prevention Oil is exemplary in its commitment to naturalness. Its formula combines five vegetable oils: avocado, sunflower, baobab, pomegranate and musk rose.

Expanscience uses sustainable sources of avocado and sunflower, with respect for biodiversity as well as local inhabitants. Its supply channels for plant-based raw materials are subject to evaluation by the Union for Ethical BioTrade (UEBT) and include precise traceability.

In accordance with Expanscience’s eco-design policy, Mustela Maternity Stretch Marks Prevention Oil is also friendly to the environment through the end of its lifecycle, thanks to a bottle that is fully recyclable.

* The remaining 1% is attributable to the need for an antioxidant (tocopherol) to maintain the product’s olfactory and general stability over time.

CARE THAT IS NATURALLY SAFE AND EFFECTIVE FOR YOUR SKIN

MUSTELA

DID YOU KNOW...?In light of the specific needs

of its target customers and its strong commitment

to Corporate Social Responsibility (CSR),

Expanscience has established its own natural products charter.

Transparent and available to the public at www.expanscience.com,

the charter serves as a detailed specification for the Expanscience

personnel responsible for formulations and procurement.

99%ingredients of natural origin in Mustela Maternity Stretch

Marks Prevention Oil

To find out more View the Expanscience natural products charter at www.expanscience.com

UNDERSTANDING

WHAT IF FEELING GOOD ABOUT YOURSELF STARTED WITH HEALTHY SKIN?

The discomfort caused by irritated skin is proof: babies cry because their bottom is sore, expectant mothers worry they’ll lose their youthful skin forever after childbirth; teenagers are embarrassed by the acne invading their face, etc. To preserve the health of their own skin or that of their child, today’s consumers are becoming more and more demanding. They’re looking for the most natural products available: 77% of mothers of infants up to age 6 months prefer to purchase products that have natural ingredients(1). They want products for their baby that are safe and enjoyable to use. For example, 61% of these mothers pay close attention to the fragrance and scent of the products they choose(1). For themselves, they value safety and effectiveness, especially to remedy stretch marks and skin tightness resulting from pregnancy. Laboratoires Expanscience address all of these concerns through a rigorous and ambitious strategy of innovation coupled with research and development.

– (1) IFOP 2015, Quantitative U&A Questionnaire on Babies, France

77 %OF MOTHERS OF INFANTS UP TO AGE 6 MONTHS PREFER TO PURCHASE PRODUCTS WITH NATURAL INGREDIENTS.

SKIN HEALTH FIRST AND FOREMOST A MATTER OF SCIENCE

IRRITATION, DRYNESS, ACNE,

STRETCH MARKS... FROM BIRTH

TO ADULTHOOD, SKIN CAN

BE SEVERELY TESTED FOR

A VARIETY OF REASONS.

FACED WITH THESE ANNOYING

PROBLEMS, CONSUMERS

WANT PRODUCTS

FOR THEMSELVES AND

THEIR FAMILIES THAT ARE SAFE,

PLEASANT AND EFFECTIVE.

THE ABILITY TO FULFILL THAT

DESIRE REQUIRES A STRINGENT

AND THOROUGH RESEARCH

AND DEVELOPMENT PROCESS.


UNDERSTANDING THE SKIN OF PREGNANT WOMEN

In order to preserve skin health, you must first have an exceptionally detailed knowledge of the physiology of skin. That’s the aim of a new chapter in Expanscience’s EV.E.I.L.S* research program, which expanded in 2015 to include research on the skin of pregnant women. These studies draw on substantial human and technological resources as well as partner research teams; coupled with the recent discovery of the role played by fibronectin, a protein, they’re providing a better understanding of the essential steps involved in the formation of stretch marks. After ground-breaking research in which cells from stretch-marked skin were compared with cells from skin without stretch marks, researchers were able to evaluate the level of fibronectin production. With the help of these new models, they could then test the specific action of different active ingredients. The results were used to select the most effective active ingredient: galactoarabinan (derived from larch), chosen for its previously unknown ability to stimulate production of fibronectin and reduce the onset of stretch marks.*EValuation of Early Infant Life : the Skin

1 2 U N D E R S T A N D I N G

SCIENTIFICALLY PROVEN EFFICACY

With regard to infants, the EV.E.I.L.S.* studies, which have previously looked at normal skin and the diaper area, have now turned their attention

to other skin issues; in particular, the study of normal skin is examining immature regulation of the flow of water to the skin. In connection with the study, Mustela Hydra Bébé Body Lotion was clinically shown to be effective on key markers for hydration. At the same time, researchers used a new technology (triboacoustics) to define and scientifically quantify skin softness, so as to demonstrate the product’s positive effects.

Innovative strategies have similarly been adopted for developing two new active ingredients intended for the cosmetics industry (see opposite). For the first, Pixalia, which targets acne-prone skin, IR&D was

able to demonstrate its effects during all four phases of acne (inflammation, bacterial growth, increase in sebum quantity, deterioration of sebum quality), through in vitro testing followed by clinical tests on volunteers. For the second, Macaline, a new active ingredient for the body, researchers turned to new investigation techniques that proved its efficacy on cellulite (even embedded cellulite), drainage and skin firmness.

X1.5IN 2015, EXPANSCIENCE INCREASED ITS R&D INVESTMENT IN MUSTELA BY 150%.

MEETING THE CHALLENGE OF NATURALNESS

To respond to international consumer demand for products that are as natural as possible, Innovation, Research & Development (IR&D) has also focused its efforts on applying Expanscience’s natural products charter, which arose out of its Corporate Social Responsibility policy. For all new product development, researchers follow strict specifications regarding natural products (see page 10). With its focus on naturalness as a strategic asset in positioning its dermo-cosmetics brands, Expanscience will be expanding its communications to consumers and healthcare professionals on the theme of natural products in 2016.

The relaunch of Mustela Maternity has provided an opportunity to redefine the territory for the product line, which is intended for new and expectant mothers. In addition to a new name that is more emotional and less technical than “Mustela 9 months,” as well as more communicative product names, the packaging has been changed to convey more femininity and glamour, highlighting the beauty of a pregnant woman. The line clearly addresses a need among women who take care of themselves and want to preserve the beauty of their skin without harming their child.

EACH EXPECTANT MOTHER IS ALSO A WOMAN

With the release of Pixalia and Macaline in 2015, expanding a portfolio that already includes some twenty cosmetic active ingredients, Expanscience is on track to meet its goal of introducing two new active ingredients each year. Pixalia, which made its debut at the In-Cosmetics trade show, is unique in its ability to treat acne in both teenagers and adult women. Sporting eco-designed packaging, Pixalia is made from cleome gynandra, a plant grown in Burkina Faso. With its threefold slimming, firming and draining action, Macaline signals Expanscience’s emergence in the market for active ingredients for the body that go beyond treatment for cellulite. Also marketed in eco-designed packaging, Macaline has a formulation based on maca, a plant already used in another active ingredient (Skinergium®) and sourced from an eco-friendly supply chain in Peru.

TWO INNOVATIVE NEW COSMETIC ACTIVE INGREDIENTS

OUR AQUALICIA ACTIVE INGREDIENT RECEIVED THE GREEN INGREDIENT AWARD GOLD MEDAL AT IN‑COSMETICS 2015, IN HONOR OF ITS ECO‑DESIGN AND ACTIVE PROPERTIES.

Intended for use in cleaning and caring for acne-prone skin in teenagers and adults, the Boréade line of products from Noviderm contains, on average, 90% ingredients of natural origin, and Boréade products are 100% eco-designed. Their formulations include quinoa peptides, a patented active ingredient with soothing properties. Quinoa peptides were developed in 2011 by researchers at Expanscience IR&D after their anti-inflammatory properties were revealed in numerous studies and discoveries regarding their use for acne.

DERMATOLOGICAL EFFICACY AND NATURALNESS

THE MUSTELA PRODUCT LINE STANDS OUT FOR ITS ETHICS, ITS SCIENCE, ITS INNOVATION AND ITS SUSTAINABILITY, ALL CONSISTENT WITH EXPANSCIENCE’S CORPORATE SOCIAL RESPONSIBILITY POLICY.


WHEN OSTEOARTHRITIS STRIKES

THE CARTILAGE IN THE HIP OR KNEE,

THE ACCOMPANYING PAIN CAN

QUICKLY BECOME DISABLING.

THE RESULTING RISK OF ISOLATION

AND SELF-EXCLUSION MAKES

OSTEOARTHRITIS THE ELEVENTH

BIGGEST SOURCE OF DISABILITY

WORLDWIDE, ALL DISABILITIES

COMBINED(1). TO ENSURE

THAT PATIENTS CAN MAINTAIN

THEIR MOBILITY, EXPANSCIENCE

HAS BEEN PROMOTING A HOLISTIC

APPROACH TO TREATING

OSTEOARTHRITIS FOR MORE

THAN 20 YEARS.

- (1) The Lancet, 2012; vol. 380, no. 9859

SOCIETY

OSTEOARTHRITIS A COMPREHENSIVE

APPROACH TO ENHANCING

MOBILITY

ADVOCATING A HOLISTIC FORM OF TREATMENT

Although there is still no cure for osteoarthritis, its effects can be mitigated and its progress slowed to improve the quality of life for patients and prevent the need for surgery or prostheses. The international recommendations on this topic, such as those of the Osteoarthritis Research Society International (OARSI), are clear: osteoarthritis requires comprehensive, coordinated treatment, both pharmacological and non-pharmacological, that enlists the help of physicians, pharmacists, physical therapists and patients themselves (lifestyle, nutrition, physical exercise, etc.).

GIVEN RISING RATES OF OBESITY AND AGING POPULATIONS IN DEVELOPING COUNTRIES, OSTEOARTHRITIS HAS EMERGED AS A GLOBAL DISEASE.

THE RISK OF DEMEDICALIZATION IN FRANCE

The decision by France’s health authorities to stop the reimbursement of so-called slow-acting anti-rheumatic drugs (SAARDs) will have an inevitable effect on patient comfort, especially for patients on a limited budget. If they are not reimbursed for their treatment, many of the five million patients diagnosed with osteoarthritis(2) may choose to forgo future visits to the physician.

A study conducted in June 2015(3) indicates that patients are unwilling to treat their osteoarthritis on their own and are in critical need of advice and support from their medical practitioner. Over time, this “demedicalization” could lead to increased rates of surgery, as can be observed in countries where medical treatment is less advanced.- (2) Out of 10 million French people affected; source: Livre blanc de l’arthrose 2015.- (3) WR Conseil study report for Laboratoires Expanscience on the impact of discontinuing reimbursement for Piasclédine 300 (meetings with groups of osteoarthritis patients in Paris, Lille and Lyon).

With 20 years of

experience in the

comprehensive treatment

of osteoarthritis,

Expanscience is stepping

up its commitment

to physicians and

pharmacists to ensure

that patient quality of life

is not adversely affected

by this decision

to demedicalize

treatment for

the disease.

In December 2015, Expanscience was selected to participate in and help fund the three-year ROAD Project (Research on Osteo Arthritis Diseases), a research program led by France’s Arthritis Foundation on chronic inflammatory rheumatic diseases. Bringing together France’s seven largest centers for basic research into osteoarthritis (including laboratories at INSERM and CNRS), the ROAD Project is designed to advance our knowledge of osteoarthritis and cell aging.

EXPANSCIENCE TEAMING UP FOR RESEARCH INTO OSTEOARTHRITIS

As patients become increasingly connected to the digital world, Expanscience is opting for digital technology to provide enhanced support.

DIGITAL TECHNOLOGYFOR HOLISTIC TREATMENT

A site devoted to Piasclédine 300 was introduced online in late 2015 to give patients the information they need regarding their disease and its treatment. The site will become available in different languages during 2016.

A customized support service for osteoarthritis patients, featuring enhanced ergonomics and content as of 2015 as well as a new community forum, will help more than 10,000 registered patients share information and advice. A Spanish version of the site for Latin America will be introduced in late 2016.

With more than 40,000 visits each month, arthrolink.com is the preeminent website on osteoarthritis for patients and healthcare professionals alike. In 2015 the site was expanded to include a list of supplemental health insurance policies that cover slow-acting anti-rheumatic drugs (SAARDs).

www.piascledine.fr

www.arthrocoach.com

www.arthrolink.com

N°1FROM MARCH TO DECEMBER 2015, PIASCLÉDINE 300 CEMENTED ITS STATUS AS THE MARKET LEADER BOTH IN UNITS SOLD IN PHARMACIES AND IN THE NUMBER OF PRESCRIPTIONS WRITTEN BY GENERAL PRACTITIONERS AND RHEUMATOLOGISTS.Source: GERS Sell-Out, CSD-CAM.


A STRATEGIC DECISION TO EMBRACE A NEW BUSINESS MODEL FOR PIASCLÉDINE 300

When Piasclédine 300 was delisted for reimbursement in France in March 2015, Expanscience was quick to foresee the impact and responded by adopting and deploying a new business model, dubbed OTX, based on over-the-counter sales of the drug in connection with a medical prescription. The entire company mobilized to carry out this major change. To reduce the risk that treatment for osteoarthritis would be removed from a medical context - a trend that would harm patient quality of life - the campaign focused on highlighting the critical support provided by healthcare professionals. Medical sales representatives increased their efforts among general practitioners and rheumatologists, and also educated pharmacy personnel to give them a better understanding of the disease.

EXPANDED OUTREACH TO PATIENTS

Expanscience launched a major initiative to make Piasclédine 300 more visible in pharmacies and to enhance its packaging, its price (now capped so as not to penalize patients) and its presentation (now in packs of 30 capsules rather than 15, more convenient for those with chronic illness). In addition, a communications campaign (web, print media, radio) was launched targeting the general public to encourage medical treatment for osteoarthritis. With the same goal in mind, the company held a press conference in September 2015. All of these actions have borne fruit: at a time of declining sales overall, Piasclédine 300 has cemented its leadership in the market for osteoarthritis treatment (see page 15).

A COMPLETE PORTFOLIO FOR RHEUMATOLOGY

In 2016, Expanscience will be consolidating this new business model with help from the other products in its portfolio: Hyalgan (injectable hyaluronic acid), Takadol (analgesic), Fixical (vitamin-calcium supplement) and Nabucox (non-steroidal anti-inflammatory). And as a guarantee of medium-term growth, Expanscience will be introducing a new drug in 2016 for first-line treatment of osteoporosis in menopausal women.

OSTEOARTHRITIS IS FRANCE’S LEADING CAUSE OF DISABILITY AMONG THOSE AGED 40 OR OLDER AND THE SECOND LEADING CAUSE OF VISITS TO GENERAL PRACTITIONERS.

1 6 S O C I E T Y

CRÉME PRÉVENTION VERGETURES BAUME RELIPIDANT STELATOPIA

MUSTELAMATERNITÉ

MUSTELASTELATOPIA

STRETCH MARKS PREVENTION CREAM

VERY HIGH PROTECTION SUN SPRAY

LIPID-REPLENISHING BALM

MUSTEL A BÉBÉ

MUSTEL AMATERNIT Y

MUSTEL A SUN CARE

MUSTEL ASTEL ATOPIA

1 2 3 VITAMIN BARRIER CREME

MASSAGE OIL • PHYSIOBÉBÉ • CLEANSING MILK • HYDRA BÉBÉ

BODY LOTION • DERMO CLEANSER • HYDRA BÉBÉ FACIAL

CREAM • 1 2 3 VITAMIN BARRIER CREME

LIPID-REPLENISHING BALM • EMOLLIENT CREAM

CREAM CLEANSER • MILKY BATH OIL

VERY HIGH PROTECTION SUN LOTION • VERY HIGH

PROTECTION SUN SPRAY 200 ML • VERY HIGH PROTECTION

SUN SPRAY 300 ML • AFTER SUN SPRAY

BUST FIRMING SERUM • BODY FIRMING GEL

LIGHT LEGS GEL • SOOTHING MOISTURIZING BALM

STRETCH MARKS PREVENTION OIL • STRETCH MARKS PREVENTION

CREAM • STRETCH MARKS RECOVERY SERUM

MUSTEL A STEL ATOPIA

A new life for eczema-prone skin.

MUSTEL A SUN CARE

Preserve their skin for the future.

MUSTEL A BÉBÉ

Efficacy, safety, pleasure of use from bir th on.

MUSTEL A MATERNIT Y

Preserve the beauty of your skin with complete

safety for your baby.

As experts in the treatment of osteoarthrit is for more

than 20 years, Laboratoires Expanscience provide

comprehensive care for osteoarthrit is of the knee

and hip and offer treatment that is proven effective,

along with services for day‑to‑day support.

RHEUMATOLOGY

DENTAL CAREDERMATOLOGY

France’s top‑selling slow‑acting symptomatic

anti‑rheumatic drug.

PIASCLÉDINE 300 MG

PROCUTA Gé 20MG HYALUGEL GEL

BUST FIRMING SERUM • BODY FIRMING GEL

LIGHT LEGS GEL • SOOTHING MOISTURIZING BALM

STRETCH MARKS PREVENTION OIL • STRETCH MARKS PREVENTION

CREAM • STRETCH MARKS RECOVERY SERUM

www.arthrocoach.com

www.arthrolink.com

www.piascledine.fr

drug

drug medical device

Source: GERS Sell‑Out CMA 2015.

FLEXEA 625 MG • FIXICAL VITAMIN D3, 1000 MG/800 UI • TAKADOL 100 MG

NABUCOX 1 G • PIASCLÉDINE 300 MG • HYALGAN 20 MG/2 ML

RHEUMATOLOGY

An exhaustive, comprehensive line of products for the treatment of osteoar thritis, calcium deficiency and pain.

DENTAL CARE

A complete product line for mouth pain, now expanded to include infant teething care

with Hyalugel 1 st teeth.

DERMATOLOGY

A wide selection of therapeutic treatments for mild to severe acne

in both adolescents and adults, and a drug for the treatment

of androgenetic alopecia in men.

drugs

SOLD ONLY IN FRANCE EXCEPT PIASCLÉDINE 300 AND FLEXEA.

DOXYLIS Gé 100 MG • EFFIZINC 15 MG

PROCUTA 40 MG • FINHAIR Gé 1 MG

drugs

SOLD ONLY IN FRANCE.

HYALUGEL SPRAY • HYALUGEL ADO

HYALUGEL 1ST TEETH • HYALUGEL GEL • HYALUGEL MOUTHWASH

medical devices

SOLD ONLY IN FRANCE.

Beyond each individual’s talents and expertise, Expanscience employees share the same vision

and are bound together by the strong, unifying traits that constitute the company’s DNA: initiative,

creativity, performance, openness, solidarity, innovation, pride in belonging and responsibility. Each

day, these characteristics, defined in the wake of a 2015 workshop on Laboratoires Expanscience’s

identity, are concretely reflected in the way we work and in projects and actions dedicated to our

collective success, all to fulfill our common mission: protecting your health through innovation.

At the heart of Laboratoires Expanscience:

each one’s potential makes everyone’s

success.

FEATURE

#OPENNESS

#RESPONSIBILITY

FLEXEA 625 MG • FIXICAL VITAMIN D3, 1000 MG/800 UI • TAKADOL 100 MG

NABUCOX 1 G • PIASCLÉDINE 300 MG • HYALGAN 20 MG/2 ML

#CREATIVITY

#PERFORMANCE

#INITIATIVE

#PRIDE

#SOLIDARITY

#INNOVATION

F o n d a t i o n M o u v e m e n tpour les Villages d’Enfants

INNOVATION

ANTICIPATING THE NEEDS OF THE FUTURE

With 87 patents registered in France and 843 patent applications filed worldwide, Expanscience has innovation in its blood! Since 1950, Expanscience’s Research & Development Center has been developing original formulations and new active principles for maintaining health. To meet that objective, the company also creates innovative services for lending support to consumers, patients and healthcare professionals.

2 2 F E A T U R E

STRENGTHENING THE TIES THAT BIND US

Commitment to the community is an integral part of Expanscience, reflected in the sponsorship activities led by the Fondation Mustela for more than three decades and the company’s proactive Corporate Social Responsibility policy, established in 2004. Consistent with that commitment, since 2015 Expanscience has been offering its workforce the opportunity to support projects by two humanitarian organizations, Care France and Action Enfance, through micro-donations, in a show of employer/employee solidarity. Employees who wish to participate can lend support to either organization through a monthly micro-donation deducted from their salary that is matched by Expanscience.

SOLIDARITY

#

#

“In order to introduce new dermo-cosmetics products and respond to the needs of consumers, we need to adopt new technology and conduct innovative research, both as a preliminary step, to take our knowledge of the skin even further, and during the actual development phase, through the use of new in vitro methods, and the clinical phase.”

LABORATOIRES EXPANSCIENCE

WERE ESTABLISHED IN 1950

FROM A COLLABORATION

BETWEEN A MANUFACTURER,

PAUL BERTHOME, AND

A PHARMACIST, CLAUDE

GUILLON. THEIR TALENT WAS

TO CREATE A MINDSET AND

AN ENTREPRENEURIAL SPIRIT

THAT CONTINUE TO DRIVE

THE WORKFORCE EVEN TODAY.

MORE THAN SIXTY YEARS LATER,

EXPANSCIENCE BRINGS NEARLY

1,000 EMPLOYEES TOGETHER

BEHIND A SHARED CULTURE

AND IDENTITY.

FRANCK MENU

Cosmetic Innovation and Development Manager

ENSURING THAT EVERYONE CAN SPUR PROGRESS

Creative companies are more agile and innovative. That’s why Expanscience is developing a culture of innovation that fosters creativity among its employees. With that goal in mind, in 2007 the company created Graine d’ID, a system of participatory innovation that lets employees propose ideas on their own or in response to specific concerns. Two hundred ideas were submitted during 2015 in a variety of areas (international development, improvements in day-to-day procedures, production, commercial development of innovations). After being evaluated by special committees, these ideas were subsequently implemented within Expanscience and will help ensure our success in the future!

CREATIVITY#

FRANCK MENU

Cosmetic Innovation and Development Manager

TAKING ACTION ON BEHALF OF SUSTAINABLE GROWTH

For more than a decade, Expanscience has been developing an ambitious – and widely hailed – policy of social and environmental responsibility that not only generates value for the company’s target audience but serves to differentiate Expanscience brands (see page 30). Taking care of young children and new and expectant mothers also means protecting their environment, so Mustela acts in every way possible to minimize the environmental impact of its products at each stage of their lifecycle.

RESPONSIBILITY#

“The eco-design we use for Mustela products, which encompasses their entire lifecycle, addresses two of the primary expectations among young mothers: naturalness and safety. As a laboratory, we feel obligated to think about what will happen at the end of each product’s life. So we take numerous concrete steps to educate consumers about proper sorting procedures in the bathroom. In my view, that’s an essential part of being a responsible dermo-cosmetics brand, especially one focused on a period of life that’s so important for the future.”

SYBILLE FOING

Mustela France Marketing Director

ADAPTING TO NEW HORIZONS

In order to innovate, improve our procedures or capture new markets, Expanscience employees need to explore new paths. This open‑minded attitude played a critical role during the initial months of Expanscience’s new Russian subsidiary, tasked with raising the Mustela brand’s profile in the various regions of the country.

OPENNESS#

“We visited numerous regional events and conventions for pediatricians to talk about the discoveries from our EV.E.I.L.S research program on infant skin from birth, and we explained exactly how and why we give priority to ingredients of natural origin in our product formulations. At the same time, in a country where mothers are very careful about the products they choose for their babies, we visited numerous ‘schools for mothers’ where we could meet with them one on one. The reception we received from both healthcare professionals and mothers suggests that there’s a very bright future for sales of Mustela in Russia.”

ARINA BAYBURTYAN

General Manager Russia


LENDING MEANING TO ALL OUR ACTIONS

Over the years Expanscience has been honored on numerous occasions for the ongoing efforts of its employees, who make a daily commitment to responsible economic growth, more virtuous products and helpful support services for its customers and healthcare professionals. This recognition is a source of pride, credibility, legitimacy and progress for a company that has always been eager for transparency regarding its offerings and its CSR policy. The past year was especially fruitful in this regard. Expanscience won awards for its CSR policy (LEEM(1) Award, the Green Ingredient Award for its cosmetic active ingredient Aqualicia, Responsible SME Award), for its services on behalf of patients and consumers (arthrocoach.com, “Mustela & me”), and for its products (2015 Family Brand Award for Mustela in the “Pregnant woman beauty products” and “Beauty & care products for children” categories; 123 Vitamin Barrier Cream voted 2016 product of the year).

(1) LEEM: Les Entreprises du Médicament, a trade organization for the French pharmaceutical industry.

PRIDE

PERFORMANCERESPONSIBLE, PRODUCTIVE GROWTH

For Expanscience, growth is inseparable from the desire to provide consumers and patients with effective, safe solutions that help to improve both their health and their quality of life. That approach, which has guided the group’s international expansion, can be seen in the treatment for osteoarthritis, an increasingly prevalent disease worldwide. In the nearly forty countries where Piasclédine 300 is distributed, our local workforce offers comprehensive treatment options for osteoarthritis patients and provides support to healthcare professionals – as in Chile, where the drug has consolidated its position as the market’s top‑selling product.

“Chile is a booming market (thanks to economic growth and high rates of osteoarthritis), but also a very competitive one. That’s why our local sales partner has an extensive team of medical sales representatives who promote Piasclédine 300 among a wide range of healthcare professionals (primarily general practitioners, rheumatologists and orthopedic surgeons). After six years on the market, our specialty is now the leading product in its category. We work with our partner to find and deploy new digital and marketing tools, to ensure we’re constantly more knowledgeable about prescribers and their needs.”

#

#

Convinced of the strong link between professional well-being and individual and collective performance, Expanscience maintains a workplace quality of life program for its employees. In line with the corporate social responsibility policy, the program aims to improve workplace practices through concrete actions and services:

PROGRAMS TO PROMOTE A WORK-LIFE BALANCE

PERFORMANCE CYCLE WITH THREE EMPLOYEE/MANAGER INTERVIEWS EACH YEAR

EMPLOYEE SATISFACTION ASSESSMENT VIA INTERNAL SURVEY

AGREEMENT ON GENDER EQUALITY AND PAY EQUITY

CONCRETE STEPS TO IMPROVE WORKPLACE QUALITY OF LIFE

HEALTH WEEKROMAIN RENARD

Area Sales Manager – Latin America

DISABILITY ACTION PLAN

AND MORE

In October 2015, Expanscience unveiled its new human resources communications campaign. Designed to encourage employee loyalty, create a cohesive workforce and attract candidates for employment, the campaign sums up the company’s identity with an explicit tagline: each one’s potential makes everyone’s success. To illustrate that belief and demonstrate the attention Expanscience gives to its men and women, the campaign describes the network of talents to which every employee contributes and the strong, unifying traits that bind the workforce together: initiative, creativity, performance, openness, solidarity, innovation, pride in belonging and responsibility.

INITIATIVE

EXPANDING THE POSSIBILITIES

For Expanscience, there’s more to preserving health than offering safe and effective products and treatments. To demonstrate that conviction, the company develops innovative services that provide support to consumers, patients and healthcare professionals – services like arthrocoach.com, a personalized digital coaching resource for people suffering from osteoarthritis.

“Arthrocoach.com works in tandem with physicians by serving as a companion that patients can use between visits to the rheumatologist. The tool helps patients progress at their own pace by coaching them on their physical activity and nutrition. Its monitoring curves give them a clearer picture of their progress and the improvements they still need to make. Available for computer, tablet or smartphone, the tool was developed in partnership with rheumatologists and experts in physical and nutritional coaching. A Spanish version for Latin America will be introduced in the near future.”

#

LAURENCE MARCHAL

Digital Manager

THE EXPANSCIENCE IDENTITYAT THE HEART OF ITS NEW “EMPLOYER BRAND”

#PRIDE

2 5E X P A N S C I E N C E

2 6 R E P O R T A G E

IR&D AND PRODUCTION

BEHIND THE SCENES IN ÉPERNON

RESPONDING TO TODAY’S CONSUMER

DEMAND AND ANTICIPATING THE DEMAND

OF THE FUTURE: THAT’S THE TWOFOLD

RESPONSIBILITY OF OUR SITE IN

ÉPERNON, HOME TO THE IR&D CENTER

AND PRODUCTION. HERE’S A LOOK AT

A KEY RESOURCE FOR EXPANSCIENCE’S

GROWTH, A SITE THAT BOASTS A WIDE

RANGE OF EXPERTISE AND CONSTANTLY

ADAPTS TO PROVIDE SUPPORT

FOR THE COMPANY’S STRATEGY.

REPORTING

2 6 R E P O R T I N G

Challenge met!The Expanscience production site has successfully kept pace with growing demand in its international markets. Production capacity for Piasclédine 300, Expanscience’s flagship anti-rheumatic drug, rose to a new high in 2015 of more than 420 million capsules. Production in dermo-cosmetics climbed to record levels as well, with 22 million Mustela bottles produced in 2015. These accomplishments are the result of employees mobilizing behind the performance plan launched in 2014 (see page 29). The outlook for 2016 is just as promising. For example, a new production line for dermo-cosmetics that came online at the start of the year will produce 10 million additional Mustela products in tube format.

What with the EV.E.I.L.S. studies on infant skin, research into the skin of pregnant women, multiple new Mustela products developed, the launch of two new cosmetic active ingredients, expanded scientific communication and more, the IR&D center had an exceptionally busy year in 2015. It also invested in the future. In addition to hiring new employees, the center acquired innovative new analytical technology for generating more sensitive and specific data. It lets researchers characterize in detail the chemical structures that make up each product (raw materials, active ingredients, finished products) so as to provide an even stronger guarantee of their quality and safety.

An intense year for the IR&D center

Based in Épernon near Paris since 1957, Expanscience is also notable for the role it plays in local economic development. An economic impact study conducted by an independent organization* offers proof: the Épernon site alone accounts for 11% of all jobs in the pharmaceutical, cosmetics and chemical sectors in the surrounding département of Eure-et-Loir. To uphold its regional role and responsibilities, Expanscience maintains an ongoing dialogue with its local stakeholders. * Local Footprint methodology, Utopies.

A key regional player

In 2015 the Épernon site unveiled a new facility devoted to molecular distillation, a process used to produce active ingredients of natural origin, including the Avocado oil and Soybean oil Unsaponifiables* used in the composition of Piasclédine 300 and the cosmetic active ingredients derived from sunflower oil. This equipment will double the site’s production capacity and drastically reduce its electricity use and water consumption (the latter by more than 10,000 m3 annually), while slashing production costs.* ASU

A NEW INSTALLATION OFFERING A THREEFOLD BENEFIT

66 MUNITS PRODUCED IN 2015, INCLUDING 44 MILLION DERMO-COSMETICS UNITS AND 22 MILLION PHARMACEUTICAL UNITS

€50 MIN INDUSTRIAL INVESTMENT OVER THE NEXT FIVE YEARS AT THE ÉPERNON SITE

1 = 31 JOB AT EXPANSCIENCE CREATES OR MAINTAINS 3 ADDITIONAL JOBS IN THE FRENCH ECONOMY


2 8 R E P O R T I N G

0302A POLICY OF CONTINUOUS IMPROVEMENT

“On a day-to-day basis, I’m responsible for checking the physical-chemical analytical reports for the raw materials and the pharmaceutical and cosmetics products that enter and leave our manufacturing site. One of the major projects in our Performance Plan is to improve how the inspection laboratory is organized. For my part, I’m working with the Innovation Research & Development Center to review some of our inspection techniques, in order to make them faster and more accurate or to bring them in line with new, more efficient technology. Our goal is to see improvement every day in the quality of the products we provide to customers.”

SONIA WASIELEWSKI /PHYSICO-CHEMISTRY TECHNICAL LEADER - INDUSTRIAL QUALITY CONTROL

COORDINATING AND MOBILIZING TO ENSURE SUCCESS

“I oversee the production unit for active principles of natural origin, such as those used to produce our Piasclédine 300 drug. I’m involved in multidisciplinary teams, with members drawn from the support functions, that manage and carry out projects for improvement. In addition to coordinating and monitoring activity in a workshop that operates 24 hours a day, 7 days a week, 315 days a year, my job is to coordinate, mobilize and empower our employees. That requires a lot of listening, communication and support to ensure we can successfully tackle the numerous challenges we face.”

STÉPHANE GENÈVE /CHEMICAL UNIT MANAGER

01

01

03

HIGH-RESOLUTION ANALYSES

“My colleagues and I develop analytical methods covering the raw material up to the finished product that are then used by the quality control staff during the production process. For that task, we now have cutting-edge analytical technology in the form of high-resolution mass spectrometry, which will enhance our analytical resources and expertise for all types of products, including raw materials, active ingredients and finished products. Thanks to this new investment, we can be even more effective and ensure even greater quality and safety in the products we bring to the market.”

NELLY LEGOUT /ANALYTICAL DEVELOPMENT PROJECT LEADER, INNOVATION, RESEARCH & DEVELOPMENT CENTER

02

04AMERICAN-STYLE QUALITY

“Our Mustela Bébé 123 Vitamin Barrier Cream is officially classified as a drug in the United States. As a result, it needed to comply with the American pharmaceutical guidelines in order to be sold in the US market. That’s what the US regulatory agency, the Food and Drug Administration, came to verify as part of an inspection at the Épernon site. That inspection, which involved several different teams at the site, offered an opportunity to review our procedures and strengthen our quality policy even further, by applying certain pharmaceutical requirements to our cosmetics products. I’m proud to have helped meet that challenge as a Quality Products Executive.”

CATHERINE GOSSET /

QUALITY PRODUCTS EXECUTIVE,

INDUSTRIAL QUALITY

05SHORTER PRODUCTION TIMES

“As an equipment operator on the cosmetic bottles line for 16 years, I participated in the Performance Plan project to see how we could improve production times. For six months, I worked alongside several of my colleagues to observe and analyze the various steps for changing bottle formats on the line, the machine configurations, the factors that contribute to breakdowns and so on. We reported on the problems we found and suggested improvements. Once new standards and handling times had been defined, we looked at how they would actually work on the ground, to ensure they were consistent and applicable for day-to-day operations. Ultimately we made a lot of progress, and I felt that this process was a real acknowledgement of my experience.”

PATRICK BAUDÉ /

EQUIPMENT OPERATOR,

DERMO-COSMETICS PRODUCTION UNIT

06EXTREMELY DEMANDING TESTS “In order to comply with the formulation specification for Mustela Maternity Stretch Marks Prevention Oil – which calls for safety, efficacy, pleasure in use, naturalness and respect for people and the environment – we tested quite a large number of plant oils. After various stability tests and toxicology studies, we selected five oils: avocado, pomegranate, sunflower, musk rose and baobab. We eventually succeeded in developing an oil for preventing stretch marks that is 99% of natural origin, that doesn’t leave a greasy film and that offers remarkable olfactory stability. I’m very proud that it received a Victoires de la Beauté consumer award in France.”

TEDDY DUPUIS /

FORMULATOR, INNOVATION,

RESEARCH & DEVELOPMENT CENTER

04


06

05

3 0 C S R S A G A

ISO 14001 CERTIFICATION OF THE ÉPERNON SITE

2O12

A SET OF CORE CSR COMMITMENTS FOR THE YEAR 2015 IS FORMALLY DEFINED

2O1O

EXPANSCIENCE BECOMES THE FIRST PHARMACEUTICAL AND DERMO-COSMETICS LABORATORY WHOSE CONTRIBUTION TO SUSTAINABLE DEVELOPMENT IS RECOGNIZED AS EXEMPLARY BY AFAQ 26000

2O13

EXPANSCIENCE BECOMES A MEMBER OF THE UNION FOR ETHICAL BIOTRADE (UEBT)

2O11

EXPANSCIENCE CELEBRATES 10 YEARS OF MEMBERSHIP IN THE UNITED NATIONS GLOBAL COMPACT, THE STARTING POINT FOR ITS COMMITMENT TO A PROACTIVE CSR POLICY

2O14

CHALLENGE MET! EXPANSCIENCE FULFILLS THE COMMITMENTS SET IN 2010*

EXPANSCIENCE LAUNCHES THE BETTER LIVING PROGRAM: ITS PROGRAM OF COMMITMENTS FOR 2020 TO HELP MAKE LIFE BETTER IN ALL OF ITS COMMUNITIES

2O15

2O16

FOR MORE THAN 10 YEARS, EXPANSCIENCE

HAS MAINTAINED A DEMANDING CORPORATE

SOCIAL RESPONSIBILITY POLICY TO IMPROVE

THE DAILY LIVES OF ITS PATIENTS AND CONSUMERS,

ENHANCE ITS VALUE TO SOCIETY AND REDUCE

ITS IMPACT ON THE ENVIRONMENT. IN THE PAST

FIVE YEARS, THIS GOAL HAS BEEN FORMALLY LAID

OUT IN AMBITIOUS OBJECTIVES THAT THE COMPANY

IS PROUD TO HAVE MET, THANKS TO A DIALOGUE

WITH ITS STAKEHOLDERS AND ITS EFFORTS TO

MOBILIZE NEARLY 1,000 EMPLOYEES WORLDWIDE.

Corporate Social Responsibility:A DECADE OF ACTIONS TAKEN AND COMMITMENTS MET

SAGA

* Except for the targets for lower energy consumption and waste production at the Épernon site

455EMPLOYEES TRAINED IN EXPANSCIENCE’S CSR POLICY IN 2015 USING THE CSR PASSPORT: A TRAINING PROGRAM (INFORMATION, COLLABORATIVE WORKSHOP, GAMES AND MORE) DESIGNED TO PROMOTE A FULLER UNDERSTANDING OF THE POLICY

12 AWARDS BESTOWED ON EXPANSCIENCE’S CSR POLICY SINCE 2012

PRODUCTS THAT ARE FRIENDLIER TO THE ENVIRONMENT

2015 objective: Expanscience will have implemented a CSR action plan for 100% of its plant supply chains

In each of its 19 supply chains for the plant raw materials that form the basis of the pharmaceutical active ingredients and certain cosmetic active ingredients used in its products, Expanscience has established an action plan to ensure respect for biodiversity and compliance with fair trade principles. This initiative has been recognized by the Union for Ethical BioTrade (UEBT) since 2011. Expanscience’s procurement policy won additional plaudits in 2015: Aqualicia, an acacia-derived cosmetic active ingredient, was honored with a Green Ingredient Award for its composition and the sustainability of its development process. In sourcing its acacia from Burkina Faso, Expanscience offers economic opportunities to a group of female harvesters and responds to local concerns regarding biodiversity protection and human development.

RESPONSIBLE SUPPLY LINES FOR PLANT RAW MATERIALS

FULFILLED

2015 objective: Establish an action plan to reduce the environmental impact of our principal drug

Piasclédine 300, an Expanscience drug used to treat osteoarthritis, was subjected to a lifecycle analysis to identify its environmental impact. Since the drying process used for avocado, the key ingredient in Piasclédine 300, is the largest contributor to the product’s environmental impact, Expanscience defined an action plan with its partner avocado producers. In Peru, for example, the plan helped to reduce natural gas consumption by 18%**. In Épernon, the Avocado oil and Soybean oil Unsaponifiables used to create the drug are then produced in a facility built to High Environmental Quality (HEQ) standards. An effluent pretreatment plant has been installed as well. Moreover, by packaging Piasclédine 300 in packs of 30 capsules rather than 15, the volume of paper and cardboard used for the product has been reduced.

** Between 2010 and 2015, per 100 units produced

2015 objective: All new Mustela and Noviderm dermo-cosmetics products will be eco-designed in 2015

“As of 2014, all new dermo-cosmetics products are subjected to our evaluation tool dubbed EENOE (from the French acronym for “Together Let’s Eco-Design Our Expanscience Products”). We use the tool to gauge the effort that went into developing a new dermo-cosmetics product, with a view to reducing its environmental impact at each stage of its lifecycle. This assessment is performed on the basis of qualitative and/or quantitative data on five factors: raw materials and formulation, primary and secondary packaging, tertiary packaging, industrial manufacture, use. To qualify as eco-designed, a new product must outperform its reference product by obtaining a higher score both overall and on at least one of the five factors. To give one example, all of the products in the Mustela Bébé range relaunched in 2014 met that standard.”

Marie-Noëlle Joinville Cosmetic Innovation and Eco-Design Manager

FULFILLED

FULFILLED


3 6 S A G A R S E

2015 objective: Reduce natural gas, electricity and water consumption and waste production at the Épernon site (IR&D and production) by 20%

“Between 2010 and 2015, our water consumption per 100 units produced was cut by 22% and our natural gas consumption by 25%, thanks to upgrades and improvements (boiler insulation, burner replacement and so on). We reduced electricity consumption by 16% by replacing compressors and optimizing lighting and climate control in the production units. These water and energy savings will increase in 2016 with the new molecular distillation facility (see page 27). Waste production, meanwhile, increased by 38.5% over the period. Seventy percent of the waste produced consists of the sludge generated when tanks are washed; if this rinse water is excluded, waste production fell by 19%. The commissioning of a second pretreatment plant in late 2016 will reduce our volumes of waste to a very substantial degree.”

Didier Levêque, Site Director

2015 objective: Reduce greenhouse-gas emissions by 20%

Our efforts have been successful! At equivalent production levels, our greenhouse-gas emissions are 25% lower than those of 2008***.

*** At equivalent production levels, excluding sourcing of raw materials and subsidiaries’ distribution activities.

ENVIRONMENTAL IMPACT REDUCED, OUR RESOURCES PRESERVED

PARTIALLY FULFILLED

-20.5 % OUR REDUCTION OF NATURAL GAS AND ELECTRICITY CONSUMPTION COMBINED BETWEEN 2010 AND 2015 AT THE ÉPERNON SITE, PER 100 UNITS PRODUCED

FULFILLED

2015 objective: introduce an employee skills development policy to promote professional development and improve the company’s performance

“Since 2010, our human resources policy has made professional development a priority. Each employee now has three annual meetings with his or her manager (annual interview, evaluation interview, career development interview). We’ve also established a monthly meeting with all managers so they can talk to their teams about the company’s direction and key projects. Moreover, we’ve led some major initiatives regarding mobility and qualifications. For example, medical sales assistants have had the chance to acquire the skills to become medical sales representatives, while machine operators received 70 hours of training to obtain a professional certificate of qualification.”

Fanny Debbi, Human Resources Director

2015 objective: Complete the Workplace Quality of Life program

Numerous actions have been taken with regard to workplace quality of life, including a campaign to promote work/life balance, enhanced medical coverage, a Health Week event held annually since 2013 for employees in France and abroad, and an employee satisfaction survey conducted since 2012. This policy has yielded dividends: in France, Expanscience was awarded the 2015 Victoire d’Or du Capital Humain award in the pharmaceutical industry, given to companies with the best HR policies.

FULFILLED

FULFILLED

EXPANDED SOCIAL RESPONSIBILITY

INCREASINGLY GLOBAL OPERATIONS, CHANGING

BUSINESS STRATEGIES, NEW STAKEHOLDER EXPECTATIONS

FOR BUSINESSES, NEW ENVIRONMENTAL AND SOCIAL

CONCERNS... ON THE STRENGTH OF A CSR POLICY

DEFINED MORE THAN A DECADE AGO, EXPANSCIENCE

IS TARGETING NEW MILESTONES WITH ITS PROGRAM

OF COMMITMENTS FOR 2020. ITS GOAL: TO HELP

IMPROVE LIVES IN EACH OF ITS COMMUNITIES (PATIENTS,

CONSUMERS, EMPLOYEES) BETWEEN NOW AND 2020,

AS PART OF THE LABORATOIRES EXPANSCIENCE

“BETTER LIVING PROGRAM”.

INNOVATE IN A RESPONSIBLE AND COLLABORATIVE WAY

This new road map is designed to make corporate social responsibility even more integral to the Expanscience organization, so that the company becomes a greater contributor to society and anticipates community needs more effectively. Building on the commitments pledged for 2010-2015, the Better Living Program contains new objectives drafted jointly by Expanscience and its internal and external communities.

PROGRESS WITH OUR COMMUNITIES

Laboratoires Expanscience are also committed to expanding their business responsibly, both in France and worldwide, by consistently combining progress with ethics in developing their innovations. Expanscience hopes to meet these challenges while making progress alongside its communities.

TAKE CARE OF OUR CUSTOMERS AND OF THEIR ENVIRONMENTS

As its way of caring for its customers and their environment, Laboratoires Expanscience and their brands pledge to provide products that are more responsible throughout their lifecycle, and to creating solutions that enhance treatment and aid prevention in the areas of skin health and osteoarthritis.

Whatnew goalsfor 2020?

Corporate Social Responsibility


3 4 H E R E & T H E R E

IN 2015 EXPANSCIENCE

REACHED A SYMBOLIC

AND DECISIVE MILESTONE.

FOR THE FIRST TIME,

ITS INTERNATIONAL

TURNOVER EXCEEDED ITS

TURNOVER IN FRANCE,

WHICH ALSO INCREASED.

HERE’S A LOOK BACK

AT HOW VARIOUS

PRODUCTS PERFORMED

IN THE PRINCIPAL

COUNTRIES WHERE

THEY ARE MARKETED.

51.3 %SHARE OF EXPANSCIENCE TURNOVER GENERATED OUTSIDE FRANCE IN 2015

HERE & THERE

A STRONGER PRESENCE

ON 5 CONTINENTS

Our performance of the past year offers proof: Expanscience is on track to meet its objective for 2020 of generating 75% of its turnover from international markets.

The share of sales outside France has risen from 44.9% in 2013 to 46.1% in 2014 and 51.3% in 2015. The acceleration over the past year can be attributed to the export success of Expanscience’s business lines and the performance of its subsidiaries.

The dermo-cosmetics business built on its past achievements and captured new ground, thanks to the relaunch of Mustela Maternity, the success of 123 Vitamin Barrier Cream and the bestsellers in the Mustela Bébé line (Dermo-Cleansing, Hydra Bébé, etc.). The rheumatology business logged an impressive increase in sales volume for Piasclédine 300 outside France (up 20%), on the strength of organic growth and consolidation of the market share first captured in 2014.Lastly, the cosmetic active ingredients and dermatology business lines (see page 38) saw turnover increase by 15% and 5% respectively.

15 %GROWTH IN PIASCLÉDINE 300 SALES BY VOLUME IN 2015

60 %SHARE OF MUSTELA TURNOVER FROM INTERNATIONAL SALES IN 2015

75 %OF TURNOVER FROM INTERNATIONAL SALES. THAT’S THE GOAL EXPANSCIENCE HAS SET FOR 2020

UNDISPUTED LEADERSHIP POSITIONS IN EUROPE

To cement Mustela’s position as Europe’s top-selling pharmacy

brand, Expanscience opened a subsidiary in Russia in June 2015. This country offers significant growth potential in the market for dermo-cosmetics baby products. Middle-class mothers in Russia are willing to spend more on quality infant care products. In its first months of operation, the new subsidiary has been working on getting its products into retail outlets and on the brand’s name recognition among healthcare professionals. Initial results for 2016 suggest Expanscience is on track to fulfill its goal of making Mustela Russia’s top-selling Premium infant brand. Our subsidiary in Poland has captured success by focusing on its launch of Mustela Maternity in a market dominated by local brands. The Turkish subsidiary, established in 2013, delivered on the promise of that booming market by gaining new market share.

Western Europe posted an impressive performance as well, thanks to the especially warm reception given to the new Mustela Maternity line and the Mustela Bébé line, which has cemented its leadership position (with market share of 50% to 70% in some countries). Italy is a perfect example of this sales momentum, with Mustela Bébé vaulting to the top of the market in pharmacy sales. The Portuguese and Spanish subsidiaries have likewise seen steady growth, despite the economic crisis. In Belgium,

where Mustela Bébé has the highest market share of any country in the world (73%), the subsidiary changed its logistics partner so as to improve the quality of service provided to customers in 2016.

In France, thanks in particular to 123 Vitamin Barrier Cream, reintroduced in 2014, Mustela Bébé increased its market share by two points, strengthening its position as the market leader well ahead of its nearest rival (all distribution channels combined). Mustela Maternity, meanwhile, garnered an excellent reception in pharmacies and logged substantial growth in the stretch marks segment (with market share up nine points). In 2016 Mustela plans to consolidate its market position in care products for infants, children, mothers and mothers-to-be. The brand will be expanding its digital and media promotions and increasing its visibility at points of sale. In addition, it will be presenting Expanscience’s R&D findings on atopic skin to healthcare professionals.

During 2015 Piasclédine 300 posted strong results

in the six Central European countries where it is marketed, particularly in Poland, the Czech Republic and Slovakia. In Russia the product was buffeted by the impact of regional geopolitics and the economic crisis. Nonetheless, positive momentum had returned by the end of the year, prompting hopes for a recovery in 2016. France’s decision in March to discontinue reimbursement for slow-acting symptomatic anti-rheumatic drugs weighed on sales of Piasclédine 300. But with Expanscience’s adoption of a new business model for its drug (see page 16), Piasclédine 300 has reasserted its market leadership, increasing its lead over its nearest competitor and gaining market share.

PIASCLÉDINE 300

EUROPE

STRONG MOMENTUM IN NORTH AND SOUTH AMERICA

Given the strong potential in Latin America,

Expanscience has hired a special regional sales manager in Brazil, tasked with boosting sales of Piasclédine 300 on the continent. The product has performed impressively in its two major markets, Chile (where it ranks first in market share) and Argentina. In Mexico, 2015 ended with a strong sales performance (a 10% increase in market share), despite an exceptionally competitive market. And in preparation for the launch of Piasclédine 300 in the Brazilian market in Spring 2016, Expanscience has selected a partner to operate in the country, which represents the biggest market for SAARDs* in South America.* Slow-Action Symptomatic Anti-Rheumatic Drugs

PIASCLÉDINE 300

The 2015 opening of a subsidiary in Canada, a country ranked among the

top 10 worldwide in purchasing power, has already produced results. Mustela reported 40% growth in Canadian sales during 2015, thanks to a sharp acceleration in the number of pharmacies stocking Mustela products, plus targeted trade campaigns that focused on the quality of the products. The Mexican subsidiary, for its part, returned to a path of growth in 2015 after reintegrating several support functions that had previously been outsourced. Its Brazilian counterpart, established in 2013, enjoyed steady growth by expanding into Brazil’s southern states and anticipates a promising year in 2016, thanks to the late-2015 launch of 123 Vitamin Barrier Cream in the world’s second largest market for the category. And in the United States, Mustela has maintained its position in the face of new rivals that have invested heavily in the media and at retail outlets.

3 6

AMERICAS

H E R E & T H E R E

OCEANIA: HIGH AMBITIONS IN AUSTRALIA

With 23.1 million inhabitants, more than 300,000 births annually and a growing economy for more than 20 years, Australia offers strong potential for Mustela. With that in mind, Expanscience established a subsidiary in the country in 2014 to boost sales, which had been handled by a distributor for the previous decade. In 2015 the subsidiary continued to anchor its standing in the market by making the brand more visible, with the aim of capturing 50% of the Premium market for infant skin care in pharmacies over the coming years. The year was also marked by a first for the subsidiary: The science committee for the Annual Scientific Meeting, a major dermatology conference in Australia, invited Expanscience to present the results of its EV.E.I.L.S. research program on infant and child skin.

AFRICA AND THE MIDDLE EAST: GROWTH DRIVERS IN THE MAKING

In September 2015, Piasclédine 300 made

a successful debut in the South African market, suggesting a positive outlook for 2016. In North Africa, sales continued to improve in Morocco – a long-standing market for Piasclédine – but were hampered in Algeria by the government’s decision to follow the path of its French counterpart in discontinuing reimbursement for anti-rheumatic drugs. The Middle East posted a solid sales performance in the three major countries managed by our Cairo-based partner: Egypt, Saudi Arabia and Iran.

After tripling its turnover on the African continent over the past four

years, Mustela continued to see strong growth in 2015, notably in Algeria, Morocco and Ivory Coast. In 2016 the brand will be targeting South Africa, the only major African country where it has not been available, in conjunction with a local partner. In addition, to oversee growth in the dermo-cosmetics business in the Middle East – a region that offers high potential, given the number of births, the extensive use of medical care and elevated purchasing power – Expanscience has opened an office in Dubai.

AFRICA

OCEANIA


PIASCLÉDINE 300

STRENGTHENING OUR STRATEGIC FOOTHOLD IN ASIA

With turnover that has doubled in just two years, Asia has emerged as

Mustela’s second biggest marketing region after Europe. This record can be attributed to Mustela Bébé’s exceptionally strong performance in China in 2015, with turnover up 180%. Expanscience has invested heavily in the brand over the past three years to increase its penetration rates at points of sale and capture this extremely promising market (with 16 million births annually). The market has been boosted by increased buying power among a substantial segment of the population, which is increasingly turning to Premium products. On the Asian continent as a whole, the Mustela Bébé and Maternity product lines have likewise posted strong growth, especially in Hong Kong and Taiwan.

In Southeast Asia, where Expanscience relies on

a local distributor to market Piasclédine 300, the year ended with a 300% increase in sales in Malaysia, the Philippines and Vietnam. To coincide with Piasclédine 300’s 2014 launch in Vietnam, two scientific symposiums highlighting Expanscience’s expertise in osteoarthritis were held with rheumatologists and other members of Vietnam’s medical community. In South Korea, where Piasclédine 300 is sold under the name Imotun, the drug consolidated its position as market leader among the products in its class over the past several years.

In France, home to Effizinc, Doxylis Gé and Procuta Gé, Expanscience offers a wide range of oral treatments for mild to severe acne in adolescents and adults. In 2014 we expanded our portfolio of dermatological drugs with Finhair Gé, formulated to treat androgenic alopecia in men ages 18 to 41. Thanks to vigorous sales of Finhair Gé coupled with increased market share for Effizinc and Doxylis Gé, the business line as a whole logged a 5% increase in turnover by drawing on its close relationships with dermatologists.

DERMATOLOGY: OUR ADDITIONAL SKIN EXPERTISE

Expanscience’s cosmetic active ingredients business, which markets cosmetic active ingredients and sensory ingredients in about fifteen countries, tallied double-digit growth in 2015, notably thanks to Aqualicia, a cosmetic active ingredient for cell hydration that was introduced in 2014. In addition to performing exceptionally well in France, its primary market, the business has expanded its sales in China, where Premium active ingredients are in growing demand among local firms seeking to move upmarket.

Soline, a moisturizing active ingredient with soothing and lipid-replenishing properties, has had a banner year in the United States thanks to the successful launch of a flagship product for a prestigious international brand. Finally, in partnership with a local distributor, Expanscience has established a presence in Turkey to serve as a launching pad for the markets in the Middle East.

SUSTAINED GROWTH FOR COSMETIC ACTIVE INGREDIENTS

ASIA

PIASCLÉDINE 300

CHILD DEVELOPMENT,

FAMILIES, PARENTHOOD,

SUPPORT FOR SENIORS...

EXPANSCIENCE IS EXPANDING

ITS PHILANTHROPIC EFFORTS

IN WAYS THAT REFLECT ITS

CORE IDENTITY. BOTH

IN FRANCE AND WORLDWIDE,

ITS COMMITMENT TRANSLATES

INTO SUPPORT FOR RESEARCH

PROJECTS AND INITIATIVES LED

BY HEALTHCARE PROFESSIONALS

AND NON-GOVERNMENTAL

ORGANIZATIONS.

A PARTNER TO RESEARCHERS

Each year the Fondation Mustela bestows awards and research grants for initiatives likely to have practical applications that improve the treatment options available to professionals in the field of child care and child health.

In 2015 the foundation awarded two grants, one on how children see health and another on parental bonds. The foundation also announced two winners of its Maieutics Prize in France for midwives. One prize was awarded to a researcher examining the institution of the contemporary family, while the second went to a study of fungicides and their impact on child development.

The Maieutics Prize is also awarded in Belgium and, as of 2015, in Poland, where the maiden winner was a research project to improve perinatal health. In addition, the Research Action Award, designed to support innovative initiatives for child development within the family or institutional environment, was given to a project studying ways to prevent conflicts in mother-child relationships.

1982CREATION OF THE FONDATION MUSTELA

120AWARDS AND RESEARCH GRANTS GIVEN BY THE FONDATION MUSTELA SINCE 1982 IN THE FIELDS OF PSYCHOLOGY, SOCIOLOGY, PSYCHIATRY AND MAIEUTICS

"From physiological to psychological, cognitive and emotional development: childhood in all its aspects has been at the heart of the projects funded by the Fondation Mustela for more than 30 years. As it has grown and developed, the Fondation Mustela has continued to support healthcare professionals and kept faith with its determination to tackle new questions and introduce new ways of working. Getting older while remaining young at heart – surely that’s the best way to grow up."

Chantal Larcade Chief Representative of the Fondation Mustela

SPONSORSHIP

A COMMITMENT

WITHOUT BORDERS

The Fondation Mustela’s website has been completely redesigned to be more informative for the general public. The site is available in two versions, one for a general audience and the other for healthcare professionals, who can order information and prevention packs at no charge or apply for the foundation’s various grants and awards.With just a few clicks, visitors can learn about the foundation’s various activities or view interactive media. Italian, Polish, Turkish, Dutch and Portuguese versions of the site are also available.

Visit us at www.fondationmustela.com

As it has each year since 1998, Laboratoires Expanscience awarded two osteoarthritis awards in 2015 for clinical and basic research, totalling €3,820 each, along with an award for dermatology research in the amount of €5,000. These awards are presented in partnership with the Société Française de Rhumatologie and the Société Française de Dermatologie respectively.

A REVAMPEDWEBSITE

A HISTORY OF SUPPORT FOR DERMATOLOGICAL AND OSTEOARTHRITIS RESEARCH

ACTIVELY WORKING IN THE FIELD BOTH IN FRANCE AND WORLDWIDE

The Fondation Mustela supports numerous initiatives targeted to children and families and led by healthcare professionals or select NGOs. In 2015, the foundation’s Social Pediatrics Prize was awarded to Dr. Valentina Dell’Orto, a physician from the Hôpital Antoine-Béclère in Clamart, France, for her project to prevent feeding difficulties in premature newborns. In Lebanon, the foundation renewed its support for ASMAE, a child protection organization associated with the NGO Soeur Emmanuelle. Always alert to international emergencies, the Fondation Mustela also awarded an exceptional grant of €40,000 to Enfance Nepal in the wake of the earthquake that struck the country on April 28, 2015.

With a presence in 20 countries, the Fondation Mustela has lent support to several Expanscience subsidiaries, including those in Italy (to help fund villages for abandoned children), Portugal (for the well-being of young patients from families experiencing difficulties) and Turkey (for early education for women to boost their career prospects). At the same time, it has worked with supply chains for plant raw materials to fund projects targeting local populations, in Burkina Faso and elsewhere.

The past year also saw the foundation step up its prevention outreach initiatives for the general public, including the reissue of an informative brochure to enhance the status of the midwifery profession and the creation of an interactive game for children, available at its website, to help them learn about bodily hygiene.

20THE NUMBER OF COUNTRIES WHERE PROJECTS HAVE RECEIVED SUPPORT FROM THE FONDATION MUSTELA

Throughout the world

FRANCE 10, avenue de l’Arche

92419 COURBEVOIE Cedex•

AUSTRALIASuite 107-108685 Burke Rd

Camberwell VIC 3124•

BELGIQUESPHERE BUSINESS PARK

Z3 Doornveld 124 2C11731 ZELLIK

• BRASIL

Rua Samuel Morse 74, Conj. 162, Berrini

04576 060 SAO PAULO

• CANADA

QC Montréal2001 Boul. Robert Bourassa Suite 17069

MONTREAL – H3A 2A6•

ESPAÑAC/Marie Curie n°7

Edificio ß – 1a planta – oficina 1.628521 Rivas-Vaciamadrid, MADRID

• ITALIA

Via Moncucco 20/2220142 MILANO

• MÉXICO

Amsterdam No 229, Piso 1– Col. HipodromoCP 06100 MEXICO, DF

• POLSKA

UI. Żelazna 67/7800-871 WARSZAWA

• PORTUGAL

Avenida António Augusto de Aguiar Nº 21 – 4º Esq. 1050-012 LISBOA

• SUISSE

Rue Jacques Grosselin, 8 CP 1035

1211 GENÈVE 26•

TURKEYBarbaros Mah. Kardelen Sok. No : 2

Palladium Tower Kat 1834746 Atasehir, İSTANBUL

• USA

60 East 56th Street, 6th FloorNew York, NEW YORK 10022

• RUSSIA

Posledny Per., 11 b.1107045, MOSCOW

www.expanscience.com

RE SOURCES - Laboratoires Expanscience€¦ · the daily diaper care that changes everything...

Documents

Transcript of RE SOURCES - Laboratoires Expanscience€¦ · the daily diaper care that changes everything...